GLP-R3

Catalogue code GLP-R3 identifies a peptide research material documented for laboratory investigation of defined receptor-signalling pathways. Compound identity is provided below for analytical reference.

Purity ≥99%Lyophilized powderLaboratory research material

Available variant

Choose a strength. The vial image, price and stock status update automatically.

SELECT STRENGTH

Retatrutide

View Cart

120,00 €

In stock

For laboratory research only. Not for human consumption.

Interested in this compound?

Contact the Phonyx team for availability and catalogue information.

Email · phonyxpept@protonmail.com

01 · RESEARCH MATERIAL OVERVIEW

GLP-R3 research material

GLP-R3 is the PHONYX catalogue code for Retatrutide. The material is presented for laboratory research and analytical reference. Its scientific relevance is based on receptor-binding and signalling characteristics described in the published literature.

The information on this page concerns compound identity, molecular targets and laboratory material specifications. It does not provide administration, dosing, treatment or self-use guidance.

Catalogue codeGLP-R3

Compound identityRetatrutide

CAS No.2381089-83-2

Molecular formulaC221H342N46O68

Approx. molecular mass≈4731 Da

FormLyophilized powder

Available vial content10 mg / 20 mg / 30 mg

CategoryMetabolic Research

02 · MECHANISM

A coordinated triple-agonist design

GLP-1 receptor

GLP-1 receptor activation is associated with intracellular signalling responses associated with GLP-1 receptor activation. It provides the established incretin foundation of the molecule.

GIP receptor

GIP receptor agonism may complement GLP-1 signalling through receptor-level signalling and downstream metabolic pathways. Its contribution is evaluated as part of the combined receptor profile.

Glucagon receptor

Glucagon receptor activation is being studied for its capacity to modulate downstream signalling relevant to metabolic pathway research, potentially extending the effect beyond single-pathway signalling.

How the receptor profile differs

Compound	GLP-1R	GIPR	GCGR
Semaglutide	✓	—	—
Tirzepatide	✓	✓	—
Retatrutide	✓	✓	✓

08 · PRODUCT SPECIFICATIONS

Phonyx portfolio formats

Compound identityRetatrutide

Available formats10 mg / 20 mg / 30 mg

FormLyophilized powder

Purity≥99%

CategoryMetabolic Research

Storage before reconstitutionCool, dry and protected from light

09 · SCIENTIFIC REFERENCES

Evidence behind the key claims

Discovery and first-in-human proof of conceptCoskun et al. Cell Metabolism, 2022 — molecular design, preclinical pharmacology and single-ascending-dose clinical data. Early phase multiple-dose studyUrva et al. The Lancet, 2022 — safety, pharmacokinetics, glycaemic effects and body-metabolic endpoint findings in metabolic research. Phase 2 metabolic research trialJastreboff et al. New England Journal of Medicine, 2023 — 338 participants, 48 weeks and dose-dependent metabolic endpoint reduction. ClinicalTrials.gov: Phase 2 metabolic research protocolNCT04881760 — official study record and protocol-level trial information. Public research registry recordNCT05929066 — published evaluation in metabolic research and overmetabolic endpoint populations. Compound reference informationEli Lilly — investigational status, triple-receptor mechanism and ongoing research programme.

10 · FAQ

Frequently asked questions

Why is it described as a triple agonist?

Because one peptide molecule activates the GIP, GLP-1 and glucagon receptors.

Research Use Only

GLP-R3 (Retatrutide) is presented exclusively as a laboratory research material. Not for human or veterinary use, consumption or administration. The listed mg values indicate total vial content only and are not dosing instructions. Product information is provided for compound identification, analytical reference and laboratory research context.